1. Scrip
  2. >>Business
  3. >>Earnings

AbbVie’s Q1 Revenue Growth Outpaces Big Pharma Peers

 
• By Joseph Haas

Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.

Business report
AbbVie delivered Q1 sales growth while peers struggled with pandemic impacts

AbbVie Inc. outperformed its big pharma peers during the first quarter, reporting 5.2% revenue growth year-over-year, totaling just over $13bn, with notable growth in its immunology, aesthetics and neuroscience portfolios. Much of that resilience came from business brought in by its 2020 acquisition of Allergan plc, and CEO Rick Gonzalez played up the company’s diversity in presenting the Q1 results.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.